Peldesine
Alternative Names: BCX 34; BCX 34 BLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator BioCryst Pharmaceuticals
- Developer BioCryst Pharmaceuticals; Nonindustrial source
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hypoxanthines; Small molecules
- Mechanism of Action Immunosuppressants; Purine-nucleoside phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cutaneous T-cell lymphoma; Eye disorders; HIV infections; Leukaemia; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 22 Aug 2001 Discontinued-Clinical for Leukaemia in USA (PO)
- 22 Aug 2001 Discontinued-II for Cutaneous T-cell lymphoma in USA (PO)
- 22 Aug 2001 Discontinued-II for HIV infections treatment in USA (PO)